Merck & Co., Inc: Uterine Cervical Neoplasms trials
The registry lists 31 Uterine Cervical Neoplasms studies with Merck & Co., Inc as lead sponsor. 3 are open to participants now and 17 have results posted.
Phase 1 4Phase 2 8Phase 3 16Phase 4 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)Not yet recruitingNCT07801027Phase 4
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RecruitingNCT07216703Phase 3
- Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in ItalyRecruitingNCT06771193
- MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)CompletedNCT05007106Phase 2Results posted
- Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)CompletedNCT04221945Phase 3Results posted
- Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)CompletedNCT03635567Phase 3Results posted
- Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)CompletedNCT03546842Phase 3Results posted
- Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)CompletedNCT03158220Phase 3Results posted
- V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)CompletedNCT01544478Phase 4Results posted
- To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung CancerTerminatedNCT01284348Phase 2Results posted
- A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).CompletedNCT01254643Phase 3Results posted
- GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)CompletedNCT01245764Phase 3Results posted
- A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)TerminatedNCT01076400Phase 1/2Results posted
- A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)CompletedNCT01047345Phase 3Results posted
- A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)CompletedNCT00943722Phase 3Results posted
- Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)CompletedNCT00851643Phase 1Results posted
- Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)CompletedNCT00543543Phase 3Results posted
- Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)CompletedNCT00092534Phase 3Results posted
- Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)CompletedNCT00092521Phase 3Results posted
- Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)CompletedNCT00092495Phase 3Results posted
- A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)CompletedNCT06894771Phase 1
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)Active, not recruitingNCT06459180Phase 3
- Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)Active, not recruitingNCT02653118
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2
- Open-label Phase 1b Study of ARQ 092 in Combination With AnastrozoleTerminatedNCT02476955Phase 1
- A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)CompletedNCT00551187Phase 2
- Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)CompletedNCT00520598Phase 2
- Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)CompletedNCT00517309Phase 3
- Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)WithdrawnNCT00365443Phase 2
- Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)CompletedNCT00260039Phase 2
- Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)CompletedNCT00092482Phase 3